Development of human pluripotent stem cell-derived hepatic organoids as an alternative model for drug safety assessment

Biomaterials. 2022 Jul:286:121575. doi: 10.1016/j.biomaterials.2022.121575. Epub 2022 May 16.

Abstract

Human in vitro hepatic models that faithfully recapitulate liver function are essential for successful basic and translational research. A limitation of current in vitro models, which are extensively used for drug discovery and toxicity testing, is the loss of drug metabolic function due to the low expression and activity of cytochrome P450 (CYP450) enzymes. Here, we aimed to generate human pluripotent stem cell-derived hepatic organoids (hHOs) with a high drug metabolic ability. We established a two-step protocol to produce hHOs from human pluripotent stem cells for long-term expansion and drug testing. Fully differentiated hHOs had multicellular composition and exhibited cellular polarity and hepatobiliary structures. They also displayed remarkable CYP450 activity and recapitulated the metabolic clearance, CYP450-mediated drug toxicity, and metabolism. Furthermore, hHOs successfully modeled Wilson's disease in terms of Cu metabolism, drug responses, and diagnostic marker expression and secretion. In conclusion, hHOs exhibit high capacity for drug testing and disease modeling. Hence, this hepatic model system provides an advanced tool for studying hepatic drug metabolism and diseases.

Keywords: Cytochrome P450; Drug metabolism; Hepatic organoid; Liver; Toxicity testing; Wilson's disease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Differentiation
  • Humans
  • Induced Pluripotent Stem Cells* / metabolism
  • Liver / metabolism
  • Models, Biological
  • Organoids / metabolism
  • Pluripotent Stem Cells*